Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection

–  Roche led the financing alongside existing and new investors –  – The funds will progress clinical programs and expand platform capabilities – SOUTH SAN FRANCISCO, Calif., Feb. 15, 2024 /PRNewswire/ -- Freenome, a biotechnology company developing blood tests for early cancer detection, announced the addition of $254 million from new and existing investors. The funding enables Freenome to advance the pipeline of single-cancer and tailored multi-cancer early detection tests built on its multiomics platfor ...